标题
Ipilimumab and radiation therapy for melanoma brain metastases
作者
关键词
-
出版物
Cancer Medicine
Volume 2, Issue 6, Pages 899-906
出版商
Wiley
发表日期
2013-10-12
DOI
10.1002/cam4.140
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pathologic and gene expression features of metastatic melanomas to the brain
- (2013) Ronald Hamilton et al. CANCER
- The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
- (2013) Emily F. Stamell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
- (2013) Maya Mathew et al. MELANOMA RESEARCH
- Concurrent whole brain radiotherapy and bortezomib for brain metastasis
- (2013) Christopher D Lao et al. Radiation Oncology
- Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
- (2012) Stephanie Du Four et al. EUROPEAN JOURNAL OF CANCER
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival
- (2012) Jonathan P. S. Knisely et al. JOURNAL OF NEUROSURGERY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgical management of melanoma brain metastases in patients treated with immunotherapy
- (2011) Russell R. Lonser et al. JOURNAL OF NEUROSURGERY
- Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
- (2011) Jeffrey S. Weber et al. MELANOMA RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants of survival in patients with brain metastases from cutaneous melanoma
- (2010) M Staudt et al. BRITISH JOURNAL OF CANCER
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma
- (2010) Thomas K. Eigentler et al. CANCER
- Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy
- (2010) Tsuguhide Takeshima et al. CANCER RESEARCH
- The Tumor-Immune Microenvironment and Response to Radiation Therapy
- (2010) Stephen L. Shiao et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Outcome predictors of Gamma Knife surgery for melanoma brain metastases
- (2010) Donald N. Liew et al. JOURNAL OF NEUROSURGERY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
- (2009) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More